N O O NH O H N O NH O O N O O H N N H NH 2 O N O N O O H H N HO O O

Maleimide-vc-PAB-MMAE

Article number:

5600203

CAS No.:

646502-53-6

Formula:

C68H105N11O15

Synonyms:

L-Valinamide, N-[[[4-[[N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-m

Molecular weight:

1316,63 g/mol

VcMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADCs with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Monomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR in a schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells. Potential mode of action/Key words: Targeting Tubulin, Cytotoxiconomethyl auristatin E (MMAE) is efficiently released from SGN-35 within CD30+ cancer cells and, due to its membrane permeability, is able to exert cytotoxic activity on bystander cells. MMAE sensitized colorectal and pancreatic cancer cells to IR ina schedule and dose dependent manner correlating with mitotic arrest. Radiosensitization is evidenced by decreased clonogenic survival and increased DNA double strand breaks in irradiated cells. Potential mode of action/Key words: Targeting Tubulin,

Inform about
Maleimide-vc-PAB-MMAE

ADCs

Cfm Oskar Tropitzsch GmbH supplies unique molecules - in this case the cytotoxins for antibodies. These payloads are ultra-toxic drugs, i.e. cytotoxic and/or cytostatic molecules, effective at a low dosage and ...

Read more

Toxins with Linkers

Cfm Oskar Tropitzsch GmbH also provides linker-drug conjugates. Either as linker-drug conjugate or under contract synthesis arrangements. To take advantage of this service please contact us info@cfmot.de for more information. Some ...

Read more